Cargando…

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species

Rezafungin is a next-generation echinocandin that has favorable pharmacokinetic properties. We compared the occurrence of paradoxical growth (PG) and trailing effect (TE) characteristics to echinocadins with rezafungin, caspofungin, micafungin and anidulafungin using 365 clinical Candida isolates be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tóth, Zoltán, Forgács, Lajos, Kardos, Tamás, Kovács, Renátó, Locke, Jeffrey B., Kardos, Gábor, Nagy, Fruzsina, Borman, Andrew M., Adnan, Awid, Majoros, László
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560028/ https://www.ncbi.nlm.nih.gov/pubmed/32824464 http://dx.doi.org/10.3390/jof6030136

Ejemplares similares

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum
por: Kovács, Renátó, et al.
Publicado: (2021)

In Vitro Killing Activities of Anidulafungin and Micafungin with and without Nikkomycin Z against Four Candida auris Clades
por: Adnan, Awid, et al.
Publicado: (2023)

In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
por: Tóth, Zoltán, et al.
Publicado: (2019)

Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis
por: Prépost, Eszter, et al.
Publicado: (2019)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
por: Glöckner, A
Publicado: (2011)

Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature
por: Kofla, G, et al.
Publicado: (2011)

Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine model
por: Forgács, Lajos, et al.
Publicado: (2020)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature
por: Wilke, MH
Publicado: (2011)

In Vivo Efficacy of Amphotericin B against Four Candida auris Clades
por: Forgács, Lajos, et al.
Publicado: (2022)

The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms
por: Tóth, Zoltán, et al.
Publicado: (2022)

Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex
por: Marx, Jana, et al.
Publicado: (2020)

Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients
por: Suh, Jin Woong, et al.
Publicado: (2020)

Unpredictable In Vitro Killing Activity of Amphotericin B against Four Candida auris Clades
por: Papp, Zoltán, et al.
Publicado: (2021)

Synergistic Interaction of Caspofungin Combined with Posaconazole against FKS Wild-Type and Mutant Candida auris Planktonic Cells and Biofilms
por: Balla, Noémi, et al.
Publicado: (2022)

In vitro and in vivo Effect of Exogenous Farnesol Exposure Against Candida auris
por: Nagy, Fruzsina, et al.
Publicado: (2020)

Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
por: Zhao, Yanan, et al.
Publicado: (2020)

Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins
por: Garcia-Effron, Guillermo
Publicado: (2020)

1412. Caspofungin and Anidulafungin Behave as Fungistatic Agents Against Candida auris
por: Dudiuk, Catiana, et al.
Publicado: (2018)

817. Caspofungin versus Anidulafungin in Patients with Candidemia: Retrospective Comparative Study
por: Elajez, Reem, et al.
Publicado: (2023)

The Neosartorya fischeri Antifungal Protein 2 (NFAP2): A New Potential Weapon against Multidrug-Resistant Candida auris Biofilms
por: Kovács, Renátó, et al.
Publicado: (2021)

1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study
por: van der Geest, Patrick J., et al.
Publicado: (2016)

Total transcriptome analysis of Candida auris planktonic cells exposed to tyrosol
por: Balla, Noémi, et al.
Publicado: (2023)

Micafungin versus caspofungin in the treatment of Candida glabrata infection: a case report
por: Yamada, Shoko Merrit, et al.
Publicado: (2016)

FKS1 mutation associated with decreased echinocandin susceptibility of Aspergillus fumigatus following anidulafungin exposure
por: e Silva, Ana Pinto, et al.
Publicado: (2020)

In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris
por: Caballero, Unai, et al.
Publicado: (2021)

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Thompson, George R, et al.
Publicado: (2020)

2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide
por: Pfaller, Michael A, et al.
Publicado: (2018)

The Role of Uniform Meropenem Usage in Acinetobacter baumannii Clone Replacement
por: Balázs, Bence, et al.
Publicado: (2021)

2111. Anidulafungin vs. Micafungin Treatment in Adult Patients with Candidemia: A Retrospective Study of Single-Center Experience
por: Suh, Jinwoong, et al.
Publicado: (2019)

Recent Insights into the Paradoxical Effect of Echinocandins
por: Wagener, Johannes, et al.
Publicado: (2017)

Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model
por: Hager, Christopher L, et al.
Publicado: (2018)

The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models
por: Cushion, Melanie T., et al.
Publicado: (2021)

A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis
por: Kohno, S., et al.
Publicado: (2012)

Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study
por: Shalhoub, Sarah, et al.
Publicado: (2014)

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
por: Thompson, George R, et al.
Publicado: (2020)

P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis
por: Thompson, G R, et al.
Publicado: (2023)

Erratum to: Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
Publicado: (2021)

Elevated Vacuolar Uptake of Fluorescently Labeled Antifungal Drug Caspofungin Predicts Echinocandin Resistance in Pathogenic Yeast
por: Jaber, Qais Z., et al.
Publicado: (2020)

2115. Activity of a Long-Acting Echinocandin Rezafungin and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018
por: Pfaller, Michael A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8mcf7jn1ibio8fi15ie6m29ofv